Eusa Pharma completes $115m acquisition of Sylvant for iMCD treatment
Eusa Pharma has successfully acquired the global rights to Sylvant (siltuximab), a drug used in the treatment of idiopathic multicentric Castleman’s disease (iMCD), from Janssen Sciences Ireland in an all-cash deal valued at $115 million. The agreement, which was initially signed in July 2018, marks a significant step for Eusa Pharma as it expands its […]